

Press Release

10 September 2003

Uppsala, Sweden

Gyros appoints Chief Financial Officer

Gyros AB announced today the appointment of Björn Bontin as Chief Financial Officer and Investor Relations Manager within the company. Mr. Bontin comes from the business systems company IBS AB where he held the position of CFO and Investor Relations Manager.

"Mr. Bontin has long experience of working in publicly listed companies and brings with him a strong network within the financial and analytical world." explained Dr. Maris Hartmanis, CEO at Gyros AB. "In addition, his experience of working in growing companies within an international environment where advanced cash management skills are essential, is well-suited to the company's global ambitions."

Former Vice President for Finance and Administration, Mathias Brandhammar, has taken the position of Administration Director.

About Gyros AB

Gyros miniaturizes and integrates laboratory applications, enabling scientists to generate more information from less sample and to improve lab performance. Using our proprietary technology platform, we increase productivity by streamlining the many steps of conventional applications into single, nanoliter scale procedures. Optimal environments are created for each application.

A Gyrolab microlaboratory, in the form of a compact disk, can process hundreds of samples in parallel, under the control of Gyrolab Workstation.

Our company will realize the full potential of the Gyros technology platform in the fields of drug discovery and diagnostics. Initial product offerings are focused towards the growing area of proteomics. Gyros has more than 90 employees working at its headquarters in Uppsala Science Park, Sweden and in sales offices in the USA and Europe.

For further information, visit www.gyros.com or contact:

Maris Hartmanis, President and CEO, Gyros AB

Tel: +46 (0)18 566 330 Mobile: +46 (0)70 562 8617

Email: <u>maris.hartmanis@gyros.com</u>

Per Sjöberg, Executive Vice President Marketing and Sales, Gyros AB

Tel: +46 (0)18 566 318 Mobile: +46 (0)70 544 4799 Email: <u>per.sjoberg@gyros.com</u>

Sue Cresswell, Marketing Communications

Tel: +46 (0)8 54472620 Mobile: +46 (0)70 551 9520 Email: <u>sue.cresswell@gyros.com</u>

Statements in this press release that are not strictly historical may be forward-looking and include risks and uncertainties. Therefore, though based on Gyros' current expectations, it should be duly noted that a variety of factors could cause actual results and experiences to differ materially from what is herein expressed. Risks and uncertainties include, but are not limited to, risks associated with the management of growth and international operations (including effects of currency fluctuations), variability of operating results, unforeseen changes in the diagnostic and pharmaceutical markets, market competition, rapid or unexpected changes in technologies, fluctuations in product demand, difficulties to successfully develop, adapt, produce or commercialize products, the ability to identify and develop new products and to differentiate products from those of competitors, as well as various legal hazards.

Gyros, Gyrolab and the Gyros logo are registered trademarks of Gyros AB.